Wave Life Sciences, Inc.

WVE

Wave Life Sciences, Inc.

WVE

Insider Sentiment (TTM):

Last Purchase:2026-03-30Last Sale:2026-02-26Shares Purchased (TTM):2,442,091Shares Sold (TTM):888,708

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:160,962,963Shares Outstanding:200,167,869Institutional Ownership Pct.:80.41%

Earnings Market Reaction:

Filing Date:2026-07-30Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	368	545	602	196	208	243	302	311	154	181	200	140
Marketable Securities	123	-	-	-	-	-	-	-	-	-	-	-
Accounts Receivable Net Current	1	0	1	10	2	-	1	0	1	0	21	7
Prepaid Expense Current	12	13	8	7	7	8	10	11	12	11	10	8
Other Assets Current	4	3	3	3	7	7	7	3	5	5	4	4
Assets Current	508	561	615	215	224	258	320	325	172	197	235	159
Assets Noncurrent
Property Plant And Equipment Net	7	7	7	8	9	10	10	11	12	12	13	14
Operating Lease Right Of Use Asset	39	11	12	14	15	17	18	19	20	22	23	24
Restricted Cash And Cash Equivalents Noncurrent	4	4	4	4	4	4	4	4	4	4	4	4
Other Assets	-	-	-	-	-	-	-	0	1	1	0	0
Other Assets Noncurrent	1	0	0	0	1	0	0	-	-	-	0	-
Assets Noncurrent	51	22	24	26	29	30	32	34	37	39	40	41
Assets	558	584	638	241	252	288	352	359	209	235	275	200
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	20	19	16	14	15	14	16	13	18	12	13	13
Accrued Liabilities And Other Liabilities	18	13	27	16	13	8	21	15	11	7	17	13
Contract With Customer Liability Current	9	9	44	47	52	57	66	136	137	141	150	68
Operating Lease Liability Current	4	8	8	8	8	8	8	7	7	7	7	6
Liabilities Current	51	50	95	86	87	87	111	171	173	166	186	100
Liabilities Noncurrent
Contract With Customer Liability Noncurrent	14	15	8	12	4	6	6	18	10	13	16	105
Operating Lease Liability Noncurrent	40	7	9	11	14	16	18	20	22	24	25	27
Liabilities Noncurrent	54	22	17	23	18	21	24	38	31	36	41	133
Liabilities	105	72	112	109	105	109	135	209	204	202	227	233
Temporary Equity Carrying Amount Attributable To P…	0	0	8	8	8	8	8	8	8	8	8	8
Stockholders Equity
Common Stock Value	1,627	1,627	1,616	1,224	1,191	1,179	1,175	1,140	951	950	935	841
Additional Paid In Capital	248	237	228	174	168	161	156	153	136	132	129	127
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Retained Earnings Accumulated Deficit	-1,422	-1,352	-1,326	-1,273	-1,219	-1,169	-1,122	-1,151	-1,089	-1,056	-1,025	-1,009
Stockholders Equity	454	512	518	125	139	172	210	142	-3	25	40	-40
Liabilities And Stockholders Equity	558	584	638	241	252	288	352	359	209	235	275	200
Accumulated Depreciation Depletion And Amortizatio…	51	50	50	49	48	47	46	45	44	44	43	42
Temporary Equity Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Temporary Equity Shares Issued	0	0	4	4	4	4	4	4	4	4	4	4
Temporary Equity Shares Outstanding	0	0	4	4	4	4	4	4	4	4	4	4
Common Stock No Par Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Issued	193	192	188	160	156	154	153	148	122	122	119	99
Shares Outstanding	193	192	188	160	156	154	153	148	122	122	119	99

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-15.16%	-18.09%	-22.61%	-	-	-	-	-	-	-	-	-
2025	-8.10%	1.99%	28.44%	24.39%	-15.56%	-4.29%	6.24%	126.24%	83.55%	-23.44%	-51.24%	-55.92%
2024	9.96%	-11.21%	16.19%	0.00%	44.43%	151.74%	-3.90%	-14.98%	-27.19%	-23.24%	-40.07%	-47.02%
2023	-	-	-	-6.32%	7.51%	8.89%	5.76%	-3.07%	-15.36%	-1.91%	-25.91%	-1.11%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	9.99	11.26	6.47	2.51	2.56	2.95	2.89	1.90	0.99	1.19	1.26	1.59
Quick Ratio	9.75	11.00	6.38	2.43	2.48	2.86	2.80	1.84	0.92	1.12	1.21	1.51
Working Capital	456.69M	511.44M	519.75M	129.59M	136.15M	170.61M	209.44M	153.79M	-1.05M	30.89M	48.93M	58.59M
Leverage & Debt
Debt to Equity	0.23	0.14	0.22	0.87	0.76	0.63	0.64	1.48	-58.79	7.96	5.74	-5.74
Debt Ratio	0.19	0.12	0.18	0.45	0.42	0.38	0.38	0.58	0.98	0.86	0.83	1.16
Efficiency & Turnover
Asset Turnover TTM	0.10	0.11	0.04	0.06	0.08	0.11	0.10	0.22	0.50	0.45	0.54	0.45
Days Sales Outstanding TTM	11.28	-	27.55	204.21	29.68	-	127.45	-	4.26	-	67.93	29.89
Receivables Turnover TTM	32.35	-	13.25	1.79	12.30	-	2.86	-	85.66	-	5.37	12.21
Per Share Metrics
Diluted EPS TTM	-0.99	-0.92	-1.21	-0.73	-0.79	-0.69	-0.70	-1.08	-0.57	-0.48	-0.54	-0.79
Free Cash Flow Per Share TTM	-0.95	-0.92	-1.12	-1.18	-1.22	-1.12	-1.10	-1.07	-1.00	-1.08	-0.19	-0.19
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-537.84%	-419.38%	-1,205.01%	-760.60%	-802.90%	-435.62%	-342.55%	-248.10%	-75.74%	-63.92%	-60.01%	-108.64%
Net Profit Margin TTM	-499.71%	-391.07%	-1,143.44%	-682.25%	-726.61%	-389.12%	-300.99%	-232.54%	-66.50%	-54.61%	-50.76%	-99.39%
Growth Metrics
Net Revenue Growth (1Y)	126.69%	62.63%	-44.54%	-70.84%	-83.82%	-74.43%	-71.55%	-28.31%	202.25%	661.49%	3,005.10%	1,947.62%
Net Income Growth (1Y)	55.90%	63.44%	110.68%	-14.43%	76.74%	82.16%	68.67%	67.73%	-44.00%	-59.27%	-64.46%	-44.43%
EPS Growth (1Y)	25.32%	32.74%	72.74%	-32.38%	39.60%	44.84%	29.42%	34.15%	-54.40%	-67.85%	-73.58%	-50.78%
Valuation Metrics
P/E TTM	-5.85	-7.90	-14.03	-10.07	-8.21	-11.69	-17.63	-7.63	-8.80	-12.93	-9.32	-7.18
P/B TTM	2.61	2.84	5.53	9.86	7.65	7.65	8.16	7.67	-185.89	31.42	13.52	-15.06
P/S TTM	29.25	30.91	160.40	68.69	59.64	45.50	53.07	17.74	5.85	7.06	4.73	7.13
Market Cap	1.19B	1.45B	2.87B	1.23B	1.07B	1.31B	1.71B	1.09B	646.34M	797.61M	535.79M	609.64M
Enterprise Value	817.28M	906.63M	2.26B	1.03B	857.44M	1.07B	1.41B	776.07M	492.38M	616.68M	335.44M	469.70M
Calculated Values
Free Cash Flow TTM	-193.15M	-185.00M	-188.21M	-198.17M	-200.12M	-181.32M	-151.96M	-141.83M	-129.62M	-139.43M	-20.55M	-20.60M
Net Debt	-368.01M	-544.59M	-602.07M	-196.22M	-208.48M	-243.08M	-302.08M	-310.95M	-153.96M	-180.92M	-200.35M	-139.94M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-03-30Purchase

Owner: Ra, Capital Management, L…

Title: -

Shares: 971,091

Price/Share: $6.50

Value: $6,312,091.50

Shares Owned: 26,975,505

Relationship: Director,TenPercentOwner

Ownership: Indirect

2026-02-26Sale

Owner: Francis, Chris

Title: See Remarks

Shares: 33,194

Price/Share: $15.04

Value: $499,237.76

Shares Owned: 61,867

Relationship: Officer

Ownership: Direct

2026-02-09Sale

Owner: Vargeese, Chandra

Title: See Remarks

Shares: 3,228

Price/Share: $13.45

Value: $43,416.60

Shares Owned: 408,246

Relationship: Officer

Ownership: Direct

2026-02-09Sale

Owner: Bolno, Paul

Title: President and CEO

Shares: 10,480

Price/Share: $13.45

Value: $140,956.00

Shares Owned: 275,520

Relationship: Director,Officer

Ownership: Direct

2026-02-09Sale

Owner: Francis, Chris

Title: See Remarks

Shares: 1,883

Price/Share: $13.45

Value: $25,326.35

Shares Owned: 61,867

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-03-30	Ra, Capital Management, L…	Director,TenPercentOwner	-	Indirect	Purchase	971,091	6.50	$6,312,091.50	26,975,505	4
2026-02-26	Francis, Chris	Officer	See Remarks	Direct	Sale	33,194	15.04	$499,237.76	61,867	4
2026-02-09	Vargeese, Chandra	Officer	See Remarks	Direct	Sale	3,228	13.45	$43,416.60	408,246	4
2026-02-09	Bolno, Paul	Director,Officer	President and CEO	Direct	Sale	10,480	13.45	$140,956.00	275,520	4
2026-02-09	Francis, Chris	Officer	See Remarks	Direct	Sale	1,883	13.45	$25,326.35	61,867	4
2026-02-09	Moran, Kyle	Officer	Chief Financial Officer	Direct	Sale	3,588	13.45	$48,258.60	134,385	4
2026-01-02	Francis, Chris	Officer	See Remarks	Direct	Sale	9,375	16.31	$152,906.25	25,000	4
2025-12-11	Gsk, Plc	TenPercentOwner	-	Indirect	Purchase	1,470,000	19.00	$27,930,000.00	18,245,691	4
2025-12-09	Moran, Kyle	Officer	Chief Financial Officer	Direct	Sale	50,036	20.14	$1,007,725.04	89,218	4
2025-12-08	Henry, Christian O	Director	-	Direct	Sale	93,445	14.40	$1,345,608.00	12,700	4
2025-12-08	Francis, Chris	Officer	See Remarks	Direct	Sale	441,031	14.66	$6,465,514.46	25,000	4
2025-12-08	Corrigan, Mark	Director	-	Direct	Sale	16,115	13.58	$218,841.70	28,815	4
2025-12-08	Tan, Aik Na	Director	-	Direct	Sale	134,218	13.59	$1,824,022.62	25,400	4
2025-12-08	Verdine, Gregory L.	Director	-	Direct	Sale	20,000	13.57	$271,400.00	275,217	4
2025-12-08	Wagner, Heidi L	Director	-	Direct	Sale	14,000	13.50	$189,000.00	44,930	4
2025-12-08	Rawcliffe, Adrian	Director	-	Direct	Sale	42,000	15.00	$630,000.00	12,700	4
2025-11-13	Ra, Capital Management, L…	Director,TenPercentOwner	-	Indirect	Purchase	1,000	6.69	$6,690.00	18,203,009	4
2025-11-13	Rawcliffe, Adrian	Director	-	Direct	Sale	16,115	6.79	$109,420.85	12,700	4
2025-08-22	Bolno, Paul	Director,Officer	President and CEO	Direct	Sale	217,351	10.10	$2,195,245.10	121,000	4
2025-08-22	Verdine, Gregory L.	Director	-	Direct	Sale	10,000	10.00	$100,000.00	285,217	4
2025-08-15	Tan, Aik Na	Director	-	Direct	Sale	21,000	9.25	$194,250.00	40,388	4
2025-08-13	Henry, Christian O	Director	-	Direct	Sale	9,670	8.81	$85,192.70	29,645	4
2025-08-05	Takanashi, Ken	Director	-	Direct	Sale	4,872	8.75	$42,630.00	5,716,303	4
2025-08-05	Tan, Aik Na	Director	-	Direct	Sale	1,127	8.75	$9,861.25	14,988	4
2025-06-13	Verdine, Gregory L.	Director	-	Direct	Sale	30,000	6.95	$208,500.00	282,517	4
2025-03-20	Henry, Christian O	Director	-	Direct	Sale	10,500	9.77	$102,585.00	16,115	4
2025-03-07	Bolno, Paul	Director,Officer	President and CEO	Direct	Sale	169,025	9.57	$1,617,569.25	338,351	4
2024-11-25	Bolno, Paul	Director,Officer	President and CEO	Direct	Sale	50,000	15.00	$750,000.00	217,351	4
2024-11-15	Bolno, Paul	Director,Officer	President and CEO	Direct	Sale	51,234	14.32	$733,670.88	217,351	4
2024-11-08	Francis, Chris	Officer	See Remarks	Direct	Sale	36,000	16.00	$576,000.00	0	4
2024-10-16	Bolno, Paul	Director,Officer	President and CEO	Direct	Sale	90,474	15.00	$1,357,110.00	268,585	4
2024-10-16	Francis, Chris	Officer	See Remarks	Direct	Sale	208,836	13.56	$2,831,816.16	0	4
2024-09-27	Gsk, Plc	TenPercentOwner	-	Indirect	Purchase	2,791,930	8.00	$22,335,440.00	16,775,691	4
2024-09-25	Moran, Kyle	Officer	Chief Financial Officer	Direct	Sale	17,146	9.00	$154,314.00	19,777	4
2024-08-21	Bolno, Paul	Director,Officer	President and CEO	Direct	Sale	48,366	5.78	$279,555.48	359,059	4
2024-04-03	Moran, Kyle	Officer	Chief Financial Officer	Direct	Sale	15,630	6.17	$96,437.10	33,921	4
2023-12-11	Kolchinsky, Peter, Ra Cap…	Director,TenPercentOwner	-	Indirect	Purchase	1,000,000	5.00	$5,000,000.00	19,202,009	4
2023-12-11	Ra, Capital Management, L…	Director,TenPercentOwner	-	Indirect	Purchase	1,000,000	5.00	$5,000,000.00	18,202,009	4/A
2023-12-07	Gsk, Plc	TenPercentOwner	-	Indirect	Purchase	3,300,000	5.00	$16,500,000.00	13,983,761	4
2023-08-23	Moran, Kyle	Officer	Chief Financial Officer	Direct	Sale	37,062	4.75	$176,044.50	46,120	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

80.41%

Inst. Shares: 160,962,963

Shares Outstanding: 200,167,869

2025-12-31

103.50%

Inst. Shares: 174,560,540

Shares Outstanding: 168,649,795

2025-09-30

83.13%

Inst. Shares: 139,437,224

Shares Outstanding: 167,739,208

2025-06-30

81.04%

Inst. Shares: 132,891,510

Shares Outstanding: 163,987,640

2025-03-31

76.33%

Inst. Shares: 124,098,818

Shares Outstanding: 162,572,026

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	160,962,963	200,167,869	80.41%
2025-12-31	174,560,540	168,649,795	103.50%
2025-09-30	139,437,224	167,739,208	83.13%
2025-06-30	132,891,510	163,987,640	81.04%
2025-03-31	124,098,818	162,572,026	76.33%
2024-12-31	121,170,568	138,277,468	87.63%
2024-09-30	115,144,909	132,563,467	86.86%
2024-06-30	91,912,653	129,527,003	70.96%
2024-03-31	88,935,247	129,271,678	68.80%
2023-12-31	86,046,090	106,097,268	81.10%
2023-09-30	69,228,774	106,025,063	65.29%
2023-06-30	68,864,836	105,462,414	65.30%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Wave Life Sciences, Inc. (WVE) — SEC Financial Statements & Analysis

Wave Life Sciences, Inc. (WVE) is a pharmaceutical preparations company, incorporated in DE. Wave Life Sciences, Inc. trades on Nasdaq as: WVE. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Wave Life Sciences, Inc. reported a 126.69% year-over-year revenue growth, a Debt-to-Equity ratio of 0.23x, a Price-to-Sales (P/S) ratio of 29.25x (TTM), a Price-to-Book (P/B) ratio of 2.61x (TTM), at a market cap of $1.19B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 126.69%
Debt To Equity: 0.23x
P/S TTM: 29.25x
P/B TTM: 2.61x
Market Cap: $1.19B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Wave Life Sciences, Inc. in?

Wave Life Sciences, Inc. (WVE) operates in the Pharmaceutical Preparations industry.

What is WVE's market cap?

Wave Life Sciences, Inc. (WVE) has a market capitalization of $1.19B as of 2026-06-30.

What exchange does WVE trade on?

Wave Life Sciences, Inc. (WVE) trades on the Nasdaq.

Where is Wave Life Sciences, Inc. incorporated?

Wave Life Sciences, Inc. is incorporated in DE.